These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 16432294

  • 1. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
    Dubakiene R, Nargela R, Sakalauskas R, Vahteristo M, Silvasti M, Lähelmä S.
    Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
    [Abstract] [Full Text] [Related]

  • 2. Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer.
    Randell J, Saarinen A, Walamies M, Vahteristo M, Silvasti M, Lähelmä S.
    Respir Med; 2005 Dec; 99(12):1485-93. PubMed ID: 16226024
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W, Levine B, Andriano K, Lavecchia C, Yegen U.
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [Abstract] [Full Text] [Related]

  • 4. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R, Creemers JP, Van Noord J, Sips A, Della Cioppa G, Thomson M, Andriano K, Kottakis J, Fashola T.
    Respiration; 2004 Oct; 71(2):126-33. PubMed ID: 15031566
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrançois G.
    Respiration; 2005 Oct; 72 Suppl 1():6-12. PubMed ID: 15915007
    [Abstract] [Full Text] [Related]

  • 6. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
    Chuchalin AG, Manjra AI, Rozinova NN, Skopková O, Cioppa GD, Till D, Kaiser G, Fashola T, Kottakis J.
    J Aerosol Med; 2005 Oct; 18(1):63-73. PubMed ID: 15741775
    [Abstract] [Full Text] [Related]

  • 7. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
    Miller CJ, Senn S, Mezzanotte WS.
    Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
    LaForce C, Prenner BM, Andriano K, Lavecchia C, Yegen U.
    J Asthma; 2005 Mar; 42(2):101-6. PubMed ID: 15871441
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Mar; 72 Suppl 1():28-34. PubMed ID: 15915010
    [Abstract] [Full Text] [Related]

  • 10. Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma.
    Lähelmä S, Vahteristo M, Metev H, Taseva M, Stamatova N, Bartha A, Schlezák J, Sairanen U.
    Respir Med; 2016 Nov; 120():31-35. PubMed ID: 27817813
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Nov; 72 Suppl 1():13-9. PubMed ID: 15915008
    [Abstract] [Full Text] [Related]

  • 12. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling.
    Eliraz A, Ramirez-Rivera A, Ferranti P, Holzer R, García JM, Turcotte C, Rapatz G, Pfister P, Overend T, Kottakis J.
    Int J Clin Pract; 2001 Apr; 55(3):164-70. PubMed ID: 11351769
    [Abstract] [Full Text] [Related]

  • 13. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
    Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G.
    J Asthma; 2003 Apr; 40(5):505-14. PubMed ID: 14529100
    [Abstract] [Full Text] [Related]

  • 14. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B, Rouzier R, Kruse M, Dobson C, Ayre G, Horowitz A, Fitoussi S.
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, Boulet LP, Naya IP, Hultquist C.
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L, Rosenborg J, Bengtsson T, Lötvall J.
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma.
    Otto-Knapp R, Conrad F, Hösch S, Metzenauer P, Maus J, Noga O, Petzold U, Kunkel G.
    Pulm Pharmacol Ther; 2008 Oct; 21(1):47-53. PubMed ID: 17475527
    [Abstract] [Full Text] [Related]

  • 18. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 19. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D, Vicaut E, Lefrançois G, Formoterol HFA group.
    Respiration; 2005 Feb; 72 Suppl 1():20-7. PubMed ID: 15915009
    [Abstract] [Full Text] [Related]

  • 20. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.
    Bodzenta-Lukaszyk A, Buhl R, Balint B, Lomax M, Spooner K, Dissanayake S.
    J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.